The in vitro cabozantinib screen was aligned with MET and RET expression and only showed efficacy in MET and RET positive LuCaP 93 cells, demonstrating that cabozantinib can elicit direct effects on SCNPC tumor cells driven by MET or RET activity. This evidence concerns the gene MET and neoplasm.